Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20, still leaving the stock ~40% above prior coverage levels. Short interest remains elevated at ~83.3M shares (~40% float), while days-to-cover expanded from ~1.0 to ~3.6. Short volume intensity declined from ~62–64% during the selloff to ~45%, signaling reduced marginal short pressure.
Hims resolved its legal dispute with Novo Nordisk, removing a major overhang and enabling it to offer branded drugs. Valuations have not recovered to pre-lawsuit levels as persistent insider selling and changes in disclosure have weighed negatively on sentiment. Consensus underestimates the inherent story in Hims emanating from growth in subscribers, sustainability and penetration in new products & markets.
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.15, indicating a -7.33% shift from the previous trading day.
Hims & Hers Health, Inc. (HIMS) closed at $23.84 in the latest trading session, marking a -7.88% move from the prior day.
Expand NYSE: HIMS Hims & Hers Health Today's Change (-7.75%) $-2.00 Current Price $23.88 Key Data Points Market Cap $5.9B Day's Range $23.77 - $27.20 52wk Range $13.74 - $70.43 Volume 2.1M Avg Vol 30M Gross Margin 60.86%
HIMS is navigating margin and regulatory pressure, but new benefits, a Novo Nordisk tie-up and platform growth could drive its next move.
Shares of Eli Lilly and Company (LLY) slipped about 1% in early Thursday trading after the drugmaker cautioned about potential safety concerns tied to compounde
Hims & Hers Health ( NYSE:HIMS ) looked like a fallen growth star earlier this year.